Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study

Rheumatology International

Volumn 37, Issue 6, 2017, Pages 865-873

  Touma, Zahi ^a   Sayani, Amyn ^b   Pineau, Christian A ^c   Fortin, Isabelle ^d   Matsos, Mark ^e   Ecker, George A ^f,g   Chow, Andrew ^h   Iczkovitz, Sandra ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b GLAXOSMITHKLINE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d Centre de Rhumatologie   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f DALHOUSIE UNIVERSITY   (Canada)

^g MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^h Credit Valley Rheumatology   (Canada)

Author keywords

B cell activating factor; Disease progression; Glucocorticoids; Lupus erythematosus, systemic; Observational study; Rheumatology

Indexed keywords

BELIMUMAB; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CANADA; CLINICAL ARTICLE; CLINICAL OUTCOME; CLINICAL PRACTICE; COMORBIDITY; DISEASE ASSESSMENT; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE UTILIZATION; HUMAN; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MULTICENTER STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOLOGIST; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG UTILIZATION REVIEW; HEALTH SERVICES RESEARCH; IMMUNOLOGY; MEDICAL RECORD; REMISSION; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CANADA; DRUG THERAPY, COMBINATION; DRUG UTILIZATION REVIEW; FEMALE; GLUCOCORTICOIDS; HEALTH SERVICES RESEARCH; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEDICAL RECORDS; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 85014612722     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-017-3682-9     Document Type: Article

References (15)

1. Bernatsky S, Joseph L, Pineau CA, Tamblyn R, Feldman DE, Clarke AE (2007) A population-based assessment of systemic lupus erythematosus incidence and prevalence—results and implications of using administrative data for epidemiological studies. Rheumatology 46:1814–1818
2. Chatham WW, Kimberly RP (2001) Treatment of lupus with corticosteroids. Lupus 10:140–147
3. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT et al (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219–2228
4. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG et al (2002) Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46:2121–2131
5. Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR (2001) Systemic lupus erythematosus. Lancet 357:1027–1032
6. Wallace DJ (2002) Management of lupus erythematosus: recent insights. Curr Opin Rheumatol 14:212–219
7. Trager J, Ward MM (2001) Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol 13:345–351
8. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG et al (2003) Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 48:3253–3265
9. Health Canada (2011) Summary basis of decision BENLYSTA, belimumab 120 mg/vial and 400 mg/vial, powder for solution, GlaxoSmithKline Inc., Submission Control Number 137699, Ontario
10. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918–3930
11. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377:72–731
12. Collins CE, Dall’Era M, Kan H, Macahilig C, Molta C, Koscielny V et al (2016) Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. Lupus Sci Med 3:e000118
13. Zonana-Nacach A, Barr SG, Magder LS, Petri M (2000) Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 43:1801–1808
14. American College of Rheumatology (1999) Guidelines for referral and management of systemic lupus erythematosus in adults. American college of rheumatology ad hoc committee on systemic lupus erythematosus guidelines. Arthritis Rheum 42:1785–1796
15. Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R et al (2010) European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 69:1269–1274